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Each year in March at the Publications Committee meeting
and the annual editorial meeting of JACC I have the
opportunity to report on the status of the Journal. I would
like to again share this report with the readers of JACC to
keep you apprised. The Journal is healthy, and the number
of submissions continues to grow. In the calendar year 2000,
the editorial office received 2,452 new manuscripts, or an
average of 204 per month. This represents a 2% increase
over the submission rate (2,402) for 1999. Over the years
the Journal has maintained a steady increase of 2% to 3%
each year, except for significantly higher increases in 1995
(16%), 1998 (16%), and 1999 (12%). In the year 2000 we
published 3,919 pages. Subscriptions to the Journal for the
year 2000 totaled 31,900. This has remained relatively stable
over the past few years.
The “impact factor” is one marker of how often the
Journal is cited. In some universities the relative enthusiasm
for promotion requires knowing the impact factor of the
journals in which the candidate publishes. Over the years
from 1995 to 1999 (the year 2000 data are not yet available),
the impact factor has risen from 5.793 to 7.368. This steady
growth reflects the fact that as the number of manuscripts
has increased, the quality of those accepted has also in-
creased, thus driving up the number of times they are cited
(and the impact factor).
In the cardiology market, focus readership scores are a
marker of how often the Journal is actually read and thus
provide a basis for pharmaceutical companies to place their
advertising. JACC continues to remain well ahead of its two
nearest cardiology journal competitors. For example the
relative readership scores for JACC in 2000 were 13,469,
and for its two closest competitors, 10,338 and 7,779. Thus,
JACC continues to have more advertising and advertising
revenue than they.
JACC has very strict rules about publishing supplements,
in order to avoid the potential for publishing pharmaceutical
sponsored symposia, which may have conscious or uncon-
scious bias. The only supplement we published this past year
(besides the ACC’s 50th Anniversary Historical Articles)
was the NIH sponsored Shock Registry, which was mailed
with the September 2000 issue. This will be a standard for
this clinical problem for years to come.
We continue to receive large numbers of manuscripts
from around the world. In the year 2000, 62% of the
submissions to JACC originated from outside the U.S. Japan
leads the foreign submissions, followed by Germany, Italy,
the U.K., Canada, France, and the Netherlands. Six trans-
lation editions of JACC continue publication: three in
Spanish, one in Portuguese (Brazil), one in Italian, and one
in Czech. In addition, a new translation of JACC is debuting
in Poland.
The clinical content of the Journal has remained the
same. We continue to publish 89% clinical articles and 11%
experimental studies (which have direct clinical relevance).
Because of the increase in numbers of submissions, our
rejection rate increased from 79% to 83% over the past year.
I know that this figure is disappointing to many authors,
whose manuscripts we must reject on the basis primarily of
priority rather than scientific content. The lag time from
acceptance to publication was averaging 16 weeks. As the
backlog has been reduced recently, we are returning to an
11-to-12-week in-press time.
Traditionally, JACC has had an editorial board of about
100 individuals whose names appear under the masthead of
JACC in each issue. Because of the expanding number of
manuscripts received, this number will be increased this year
to 200, and those accepting will be given stricter guidelines
regarding the number of manuscripts to be reviewed. We
are especially grateful to them and to all of you who
regularly review for JACC. Without the unselfish support of
many of you, the work of the Journal would be impossible.
The tenure of the current editors is rapidly approaching
10 years, and this is the last year we will be receiving
manuscripts. The Publications Committee conducted a
nationwide search for a replacement editor. To avoid a
conflict of interest, I was not part of the selection process.
The final three candidates were interviewed by the entire
committee in Chicago, and Dr. Anthony DeMaria, Chief of
Cardiology at the University of California San Diego, was
selected as the new Editor-in-Chief to follow us. He will be
an outstanding editor and will clearly take JACC to new
heights. Over the past few years we have gradually been
moving into the electronic age. JACC is available in its
entirety on the web page of Elsevier (Cardiosource), which
has been a great resource for searching current and back
issues. Cardiosource currently has about 50,000 subscribers,
with about 70,000 visitor sessions to the website each
month. Additional plans to move further into the electronic
age will be implemented by Dr. DeMaria as he takes over
the leadership of JACC next year.
As Editor of JACC these past 10 years, I have really
appreciated the comments and suggestions I have received
from a loyal readership. It has been a privilege for all of us
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here in the San Francisco office of JACC to be involved with
the College’s flagship publication. We look forward to
watching its continued growth and success in the next 10
years.
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